Hidden Lake Asset Management LP decreased its position in Tempus AI, Inc. (NASDAQ:TEM – Free Report) by 39.9% in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 23,095 shares of the company’s stock after selling 15,315 shares during the period. Hidden Lake Asset Management LP’s holdings in Tempus AI were worth $1,864,000 as of its most recent filing with the SEC.
Several other hedge funds have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in shares of Tempus AI by 22.1% in the third quarter. Vanguard Group Inc. now owns 9,441,607 shares of the company’s stock valued at $762,032,000 after acquiring an additional 1,706,837 shares in the last quarter. Franklin Resources Inc. boosted its position in Tempus AI by 0.4% in the third quarter. Franklin Resources Inc. now owns 1,456,120 shares of the company’s stock worth $117,523,000 after purchasing an additional 5,375 shares during the last quarter. BNP Paribas Financial Markets boosted its position in Tempus AI by 312.7% in the third quarter. BNP Paribas Financial Markets now owns 1,274,549 shares of the company’s stock worth $102,869,000 after purchasing an additional 965,730 shares during the last quarter. AQR Capital Management LLC grew its stake in Tempus AI by 6.4% in the 3rd quarter. AQR Capital Management LLC now owns 904,872 shares of the company’s stock valued at $73,032,000 after purchasing an additional 54,692 shares during the period. Finally, Clear Street Group Inc. bought a new position in Tempus AI in the 3rd quarter valued at $57,821,000. Institutional investors own 24.22% of the company’s stock.
Insider Buying and Selling
In other news, CAO Ryan M. Bartolucci sold 2,902 shares of Tempus AI stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $59.05, for a total value of $171,363.10. Following the completion of the transaction, the chief accounting officer owned 41,159 shares in the company, valued at $2,430,438.95. This trade represents a 6.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CFO James William Rogers sold 10,084 shares of the business’s stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $59.05, for a total transaction of $595,460.20. Following the completion of the sale, the chief financial officer directly owned 101,166 shares in the company, valued at approximately $5,973,852.30. This trade represents a 9.06% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 570,143 shares of company stock worth $35,595,055 in the last quarter. 26.27% of the stock is currently owned by company insiders.
Wall Street Analysts Forecast Growth
Read Our Latest Stock Analysis on TEM
Tempus AI Stock Performance
Shares of TEM opened at $49.98 on Monday. Tempus AI, Inc. has a 1 year low of $36.22 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.52, a current ratio of 3.13 and a quick ratio of 3.00. The stock’s fifty day moving average price is $59.20 and its two-hundred day moving average price is $71.69. The firm has a market cap of $8.93 billion, a PE ratio of -35.45 and a beta of 5.29.
Tempus AI Company Profile
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
Further Reading
- Five stocks we like better than Tempus AI
- The $8,000 Gold Call Every Retirement Saver Needs to Read Right Now
- A personal warning from Martin Weiss (Please read)
- Elon Musk: This Could Turn $100 into $100,000
- ~$1.5T SpaceX IPO: Pre-IPO Opportunity
- America’s gold reserves are priced at $42. The real price is $6,000+.
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
